Use of protocadherins in methods of diagnosing and treating cancer
AssigneeReverse BioEngineering, Inc.
InventorMichael D. West
Life of this patent
Estimating the term…
Abstract
Compositions and methods are disclosed for targeting the clustered protocadherins for therapeutic effect. More specifically, compositions and methods are disclosed to modify select isoforms in the α, β, and γ cluster to promote tissue regeneration or to target and reduce tumor burden in diverse cancer types. The methods have application in veterinary and human medicine.
Claims30
A method for treating cancer in a subject, a method comprising steps:
- 1) obtaining a biological sample from the subject comprising cancer cells;
- 2) identifying cancer cells that exhibit an embryonic phenotype;
- 3) identifying one or more isoforms of a clustered protocadherin locus expressed in the cancer cell that exhibit an embryonic phenotype;
- and 4) administering to the subject an anti-cancer vaccine comprising an antigen, thereby inducing an immune response.
(canceled)
-10. (canceled)
-21. (canceled)
A method for inducing an immune response against mammalian cancer cells in a subject, comprised of the steps:
- 1) obtaining a biological sample from the subject comprising cancer cells;
- 2) identifying cancer cells that exhibit an embryonic phenotype;
- 3) identifying one or more isoforms of a clustered protocadherin locus expressed in the cancer cell that exhibit an embryonic phenotype;
- and 4) administering to the subject genetically-modified immune cells capable of generating an immune response to the cancer in the subject.
-28. (canceled)
(canceled)
-35. (canceled)
A method for inducing an immune response against mammalian cancer cells in a subject, comprised of the steps:
- 1) obtaining a biological sample from the subject comprising cancer cells;
- 2) identifying cancer cells that exhibit an embryonic phenotype;
- 3) identifying one or more isoforms of a clustered protocadherin locus expressed in the cancer cell that exhibit an embryonic phenotype;
- and 4) administering to the subject an immunoglobulin superfamily member to direct an immune response specifically to the cancer cells.
-53. (canceled)
-57. (canceled)
-60. (canceled)
Dependencies are inferred from the claim text.